Alzheimer's drug results boost Elan, Wyeth

Wyeth and Elan's shares were up today as the companies announced potentially promising results from a phase II trial of bapineuzumab, an Alzheimer's treatment. The study did not attain statistical significance on the efficacy endpoints in the overall study population, but the vaccine helped patients without a gene known as ApoE4. About 70 percent of Alzheimer's sufferers don't have the ApoE4 gene. A spokesperson for the company said the results support the decision to move bapineuzumab into Phase III trials.

- see this release for more

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.